Earnings Feed
Sign Up
Home/Filings/4/0001209191-21-008925
4//SEC Filing

5AM Ventures VI, L.P. 4

Accession 0001209191-21-008925

CIK 0001817229other
View on SEC.govCompany Profile

Filed

Feb 8, 7:00 PM ET

Accepted

Feb 9, 6:03 PM ET

Size

26.6 KB

Accession

0001209191-21-008925

Insider Transaction Report

Form 4
Period: 2021-02-09
Vor Biopharma Inc.VOR
5AM Opportunities I (GP), LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2021-02-09$18.00/sh+444,444$7,999,992→ 1,858,470 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2021-02-09−19,230,768→ 0 total(indirect: See footnote)
    → Common Stock (1,414,026 underlying)
  • Conversion

    Series B Preferred Stock

    2021-02-09−19,230,768→ 0 total(indirect: See footnote)
    → Common Stock (1,414,026 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,414,026→ 1,414,026 total(indirect: See footnote)
  • Conversion

    Series A-2 Preferred Stock

    2021-02-09−45,000,000→ 0 total(indirect: See footnote)
    → Common Stock (3,308,822 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,414,026→ 4,722,848 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-02-09+3,308,822→ 3,308,822 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-02-09$18.00/sh+111,111$1,999,998→ 4,833,959 total(indirect: See footnote)
Schwab Andrew J.
10% Owner
Transactions
  • Conversion

    Common Stock

    2021-02-09+3,308,822→ 3,308,822 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-02-09$18.00/sh+111,111$1,999,998→ 4,833,959 total(indirect: See footnote)
  • Conversion

    Series A-2 Preferred Stock

    2021-02-09−45,000,000→ 0 total(indirect: See footnote)
    → Common Stock (3,308,822 underlying)
  • Conversion

    Series B Preferred Stock

    2021-02-09−19,230,768→ 0 total(indirect: See footnote)
    → Common Stock (1,414,026 underlying)
  • Conversion

    Series B Preferred Stock

    2021-02-09−19,230,768→ 0 total(indirect: See footnote)
    → Common Stock (1,414,026 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,414,026→ 4,722,848 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-02-09+1,414,026→ 1,414,026 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-02-09$18.00/sh+444,444$7,999,992→ 1,858,470 total(indirect: See footnote)
5AM Ventures VI, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2021-02-09$18.00/sh+111,111$1,999,998→ 4,833,959 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-02-09$18.00/sh+444,444$7,999,992→ 1,858,470 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-02-09+3,308,822→ 3,308,822 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-02-09+1,414,026→ 4,722,848 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-02-09+1,414,026→ 1,414,026 total(indirect: See footnote)
  • Conversion

    Series A-2 Preferred Stock

    2021-02-09−45,000,000→ 0 total(indirect: See footnote)
    → Common Stock (3,308,822 underlying)
  • Conversion

    Series B Preferred Stock

    2021-02-09−19,230,768→ 0 total(indirect: See footnote)
    → Common Stock (1,414,026 underlying)
  • Conversion

    Series B Preferred Stock

    2021-02-09−19,230,768→ 0 total(indirect: See footnote)
    → Common Stock (1,414,026 underlying)
5AM Partners VI, LLC
10% Owner
Transactions
  • Conversion

    Common Stock

    2021-02-09+3,308,822→ 3,308,822 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-02-09$18.00/sh+111,111$1,999,998→ 4,833,959 total(indirect: See footnote)
  • Conversion

    Series A-2 Preferred Stock

    2021-02-09−45,000,000→ 0 total(indirect: See footnote)
    → Common Stock (3,308,822 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,414,026→ 1,414,026 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2021-02-09−19,230,768→ 0 total(indirect: See footnote)
    → Common Stock (1,414,026 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,414,026→ 4,722,848 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-02-09$18.00/sh+444,444$7,999,992→ 1,858,470 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2021-02-09−19,230,768→ 0 total(indirect: See footnote)
    → Common Stock (1,414,026 underlying)
5AM Opportunities I, L.P.
10% Owner
Transactions
  • Conversion

    Common Stock

    2021-02-09+1,414,026→ 4,722,848 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2021-02-09−19,230,768→ 0 total(indirect: See footnote)
    → Common Stock (1,414,026 underlying)
  • Conversion

    Series B Preferred Stock

    2021-02-09−19,230,768→ 0 total(indirect: See footnote)
    → Common Stock (1,414,026 underlying)
  • Conversion

    Common Stock

    2021-02-09+3,308,822→ 3,308,822 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-02-09$18.00/sh+444,444$7,999,992→ 1,858,470 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-02-09$18.00/sh+111,111$1,999,998→ 4,833,959 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-02-09+1,414,026→ 1,414,026 total(indirect: See footnote)
  • Conversion

    Series A-2 Preferred Stock

    2021-02-09−45,000,000→ 0 total(indirect: See footnote)
    → Common Stock (3,308,822 underlying)
Footnotes (3)
  • [F1]Each share of Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.
  • [F2]The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Ventures VI, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.
  • [F3]The shares are directly held by 5AM Opportunities I, L.P ("Opportunities LP"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities LP. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities LP. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities LP, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Documents

1 file

Issuer

Vor Biopharma Inc.

CIK 0001817229

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001753037

Filing Metadata

Form type
4
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 6:03 PM ET
Size
26.6 KB
View on SEC.gov